Kornimate/medical-research-clean huggingface dataset:
results of repair of triangular fibrocartilage complex tears using mini anchor:

Conditions: Triangular Fibrocartilage Complex Tears

Summary: the triangular fibrocartilage complex (tfcc) is a grouping of ligaments and cartilage in the wrist the tfcc is comprised of six major components: the distal radioulnar ligaments (dorsal and volar), central articular disk, meniscus homolog, ulnar collateral ligament, ecu subsheath, and the ulnolunate (ul)/ulnotriquetral (ut) ligaments. this is important for wrist motion, stabilization, and overall hand function, including grip strength may progress to persistent pain, instability of the distal radioulnar joint, and arthritis if left untreated.. the tfcc vascularity is supplied by the anterior interosseous and ulnar arteries, although only a quarter of the tfcc is perfused. the limited vascularity of the tfcc, combined with its intricate soft tissue structure and torsional and axial stresses, makes the tfcc prone to frequent injury while maintaining a limited ability to heal. injuries like a fall on the outstretched hand or a forced ulnar deviation of the wrist can lead to an acute tfcc tear. tfcc tears are a common cause of ulnar sided wrist pain and can be caused by chronic degeneration or traumatic injury. acute or chronic triangular fibrocartilage complex (tfcc) tears may result in persistent ulnar-sided wrist pain, loss of grip strength, and loss of function for patients. a combination of clinical history, physical examination, and magnetic resonance imaging (mri) may be used to diagnose a tfcc lesion, but confirmation of pathology requires an arthroscopic assessment. arthroscopic assisted repair techniques have revolutionized surgical management treatment of tfcc using mini anchor arthroscopically providing many benefits. functional outcome using mayo wrist score after arthroscopic repair of triangular fibrocartilage complex tears using mini anchor


Eligibility criteria:
inclusion criteria: - peripheral traumatic tears of triangular fibrocartilage complex in both sexes aged from teenagers to sixty. b. exclusion criteria: 1. degenerative tears of triangular fibrocartilage complex. 2. central- or radial-sided triangular fibrocartilage complex tears. 3. tears associated with bony injuries. -
safety, tolerability and preliminary efficacy of erythrocyte-αpd-1 conjugate in patients with advanced malignancies

Conditions: Cancer; Solid Tumor; Hematologic Malignancy

Summary: this is an investigator-initiated, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of erythrocyte-αpd-1 conjugates in patients with advanced malignancies

this is an investigator-initiated, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of erythrocyte-αpd-1 conjugates in patients with unresectable or metastatic advanced malignancies who have failed previous systemic therapy. the study was divided into two phases: dose escalation and dose expansion

Eligibility criteria:
inclusion criteria: 1. the subject signs an informed consent form, understands this study, is willing to follow and has the ability to complete all experimental procedures; 2. regardless of gender, aged 18 to 75 years old (including threshold); 3. patients with advanced malignant tumors who have been confirmed by histopathology; 4. patients with histopathologically confirmed unresectable or metastatic solid tumors who have failed systemic treatment or have no effective standard treatment, or who are unwilling to accept standard treatment or are not suitable for standard treatment; 5. ecog≤1； 6. expected life ≥ 3 months； 7. male participants, their spouses, and female participants of childbearing age should agree to use a medically recognized effective contraceptive method from the signing of the informed consent form until 3 months after the last administration; pregnancy testing results for women of childbearing age within ≤ 7 days before the first trial drug administration must be negative. women of childbearing age include premenopausal women and women within 2 years after menopause. exclusion criteria: 1. people with other serious medical diseases, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc., and people with uncontrollable or serious cardiovascular diseases, 2. patients with clinical symptoms and the need for repeated drainage of pleural and ascitic fluids; 3. previous or recent history of pulmonary fibrosis, severe lung function damage caused by pneumoconiosis, radiation pneumonia, and drug-related pneumonia; 4. there have been adverse events related to the use of io drugs that require permanent cessation of io treatment; 5. known to have other malignant tumors, currently progressing or completing treatment at least once in the past 3 years. 6. subjects with symptomatic central nervous system (cns) metastasis confirmed by imaging or pathological examination and clinically unstable for at least 14 days prior to enrollment who require steroid treatment; 7. having hereditary bleeding tendencies or coagulation disorders, or a history of thrombosis, hemolysis, or hemorrhagic diseases; received significant surgical treatment or obvious traumatic injury within 28 days prior to the start of research treatment

Keywords: cancer solid tumor hematologic malignancy
total hip registry

Conditions: Osteoarthritis

Summary: objective describe the clinical and demographic characteristics of patients who undergo hip arthroplasty and document post operative outcomes. examine the relationship between processes of care, hospital and surgeon associated outcomes provide expanded data to characterize existing and evolving practice patterns, delivery of care, and resource utilization in the management of knee arthroplasty patients. analyze and design ancillary studies to address unanswered questions. disseminate findings through publication in peer-reviewed scientific journals.


Eligibility criteria:
inclusion criteria: * patient requires total hip arthroplasty * patient has signed irb approved informed consent exclusion criteria: * less than 21 years of age * patient is a prisoner

Keywords: total hip
michigan early disease progression cohort

Conditions: COPD

Summary: the aim of this project is to develop a disease progression cohort within the university of michigan health system to capture pulmonary function, symptom assessments and quantitative imaging among patients at risk for or with an established diagnosis of copd, focusing however on "early" copd (age 30-55 and gold stage 0,1, 2, and prism).

participants between the ages of 30-55 with at least 10 pack-year smoking history will be enrolled into a observational longitudinal cohort. during the course of the study, additional funding was secured, so data could be collected for a 3-year period from participants. some of the cohort are co-enrolled in another study (nct05033990) where they received a ct scan as part of the study. those participants will not be re-scanned during the course of this study.

Eligibility criteria:
inclusion criteria: * gold 0 participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator fev1/fvc ≥ 0.70 and fev1 ≥ 80% predicted. * preserved ratio impaired spirometry (prism) participants shall be between ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator fev150-79% predicted and fev1/fvc \> 0.70. * gold 1 participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator fev1/fvc \ = 80% predicted. or * gold 2 participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator fev1/fvc \< 0.70 and fev1 50-79% predicted. exclusion criteria: * severe asthma, which is defined as any of the following: current (i.e., at the time of the visit) gina step 4 or higher therapy (medium dose ics/laba or high dose ics or add-on lama; medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). we will accept low-dose ics/laba or medium dose ics. or 3 or more unscheduled healthcare visits (provider/urgent care/er) for asthma in the past 12 months or one asthma hospitalization in the past 12 months * concurrent participation in a therapeutic trial where treatment is blinded. * active pregnancy at the time of the baseline or return visits. this special population is being excluded to minimize potential for fetal radiation exposure. * cognitive dysfunction that prevents the participant from completing study procedures. * bmi \> 35.0 kg/m2 at baseline, due to the effects of body weight on ct scan imaging quality. * the presence of a respiratory condition other than copd or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g., dyspnea or decreased exercise tolerance). * any illness expected to cause mortality in the next 3 years. * any implanted metallic devices or prosthesis above the waist that could degrade thoracic ct scan image quality. * history of thoracic radiation or thoracic surgery with resection of lung tissue

Keywords: early copd copd smoking capture rethinc
a study comparing protected early weightbearing versus non-weightbearing after surgery for achilles tendon rupture

Conditions: Achilles Tendon Rupture

Summary: the purpose of this study was to determine the effect of protected early weightbearing (pewb) compared to non-weightbearing (nwb) after surgery for an achilles tendon rupture (atr) on health related quality of life (hrql) in the initial six week period after surgery, functional recovery over time, return to work and activity and complications. we hypothesized that pewb following atr repair would result in: i) improved hrql in the initial postoperative period, ii), a quicker recovery of hrql, strength and endurance, iii) earlier return to work and sport, and iv) no increase in complications, such as re-rupture compared to nwb.

achilles tendon rupture (atr) is commonly treated with open surgical repair. following surgical repair, there are a variety of protocols, ranging from complete immobilization to immediate postoperative mobilization with early weightbearing. however, no clear consensus regarding the optimal postoperative rehabilitation protocol for atrs exists. early rehabilitation after atr has been shown to be beneficial in animal and human studies. human prospective studies and randomized controlled trials have shown that early postoperative mobilization do not pose additional risks compared to cast immobilization, with a trend toward a reduction in lost work days and an earlier return to sport. however, these trials define early postoperative mobilization differently (i.e. use different combinations of weightbearing and range of motion). this makes it difficult to determine which factor in the early rehabilitation process plays an important role in optimizing recovery. an important component of early rehabilitation is weightbearing. comparison: patients weightbearing in the early rehabilitation period after surgical repair of the achilles tendon compared to patients non-weightbearing after the surgical repair of the achilles tendon repair. with the exception of weightbearing status, both groups performed the same rehabilitation program.

Eligibility criteria:
inclusion criteria: * closed and complete achilles tendon rupture * seen within 14 days of injury in hospital exclusion criteria: * unwilling to follow the study's rehabilitation protocol * unable to speak or read english * co-morbid conditions such as diabetes and neurological or collagen disease * pregnancy * recent immunosuppressant or fluoroquinolone therapy * previous achilles tendon symptoms * previous ipsilateral rupture * sustained an additional injury not allowing weightbearing * an achilles tendon avulsion injury * unfit for surgery

Keywords: achilles tendon rupture open surgical repair early functional mobilization weightbearing rehabilitation
analysis of circulating tumor markers in the blood (alcina)

Conditions: Cancer

Summary: exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

exploratory multi-cohort study including different types of cancer (different organs and/or different histological types). each kind of blood-borne biological markers analyses corresponds to a cohort.

Eligibility criteria:
inclusion criteria: 1. patient with any tumoral disease (proven or suspected), of any type and stage 2. more than18 years old 3. signed informed consent form additional inclusion criteria if a tumor sample is needed: 4. tumor considered as accessible by biopsy 5. normal blood coagulation tests on the last blood analysis non-inclusion criteria: 1. patient in detention or protected by the law 2. patient who cannot comply with the study follow up for geographical, social or psychological reasons additional non-inclusion criteria if a tumor sample is needed: 3. anticoagulant or antiaggregant that cannot be interrupted for the biopsy 4. central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)

Keywords: cancer circulating tumor biomarkers circulating tumor dna circulating tumor cell (ctc)
multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy post approval registry

Conditions: Heart Failure

Summary: madit-crt par is an fda mandated follow-up registry for patients that participated in the madit-crt ide study examining long-term mortality. (madit-crt ide: nct00180271)

the registry is designed to determine the long-term mortality benefit as a result of cardiac resynchronization therapy with defibrillation (crt-d) vs. implantable cardioverter defibrillator (icd) therapy in the madit-crt study patient population. the registry will collect data on patients that previously participated at madit-crt sites within the us through five years of participation from their orginal enrollment in the madit-crt ide study (madit-crt ide: nct00180271).

Eligibility criteria:
inclusion criteria: * active patients who were enrolled in the madit-crt ide (nct00180271)within the united states exclusion criteria: * patients who are unable or unwilling to comply with the protocol requirements
minimally invasive open excisional hemorrhoidectomy compared to conventional open excisional hemorrhoidectomy: a clinical trial

Conditions: Hemorrhoidectomy; Hemorrhoids Third Degree; Hemorrhoidal Disease; Postoperative Pain

Summary: this study aims to demonstrate that open excisional hemorrhoidectomy (oeh), when performed using a minimally invasive approach, results in less postoperative pain and comparable outcomes to conventional oeh.

at our hospital, the investigators have developed a new approach to hemorrhoid surgery by modifying the traditional open excisional hemorrhoidectomy. this new method incorporates an image-amplifying device and utilizes microsurgery tools. preliminary results have shown significant improvement in patients' immediate postoperative pain, with efficacy comparable to conventional methods one year after treatment. we propose conducting a clinical trial to confirm these initial findings. the study will include two gropus: one undergoing conventional open excisional hemorrhoidectomy (oeh) and the other receiving minimally invasive open excisional hemorrhoidectomy (mioeh). patients will be randomly assigned to one of these two groups. the primary outcome of interest will be the level of postoperative pain assessed 10 days after surgery. the secondary outcomes will evaluate the effectiveness of the technique one year post-surgery, measured by the hemorrhoidal disease symptom score(hdss) and the short health scale in hemorrhoidal disease (shshd).

Eligibility criteria:
inclusion criteria: * age older than 18 years. * hemorrhoids grade iii. * surgical indication for hemorrhoidal disease. exclusion criteria: * acute hemorrhoidal disease. * previous hemorrhoidal surgery. * concomitant anal fissure. * concomitant anal fistulae. * concomitant rectal prolapse. * concomitant inflamatory bowel disease or anal cancer. * language impairment.

Keywords: hemorrhoidal disease minimally invasive open excisional hemorrhoidectomy open excisional hemorrhoidectomy
the impact of the timing of trigger on ivf success

Conditions: Fertilization in Vitro; Infertility; Embryonic Development

Summary: the aim of this study is to examine the length of ovarian stimulation with the timing of trigger in an ivf cycle and its potential to impact patient outcomes.


Eligibility criteria:
inclusion criteria: * planning to move forward with an ivf cycle * have met the requirements of being a patient at ccrm colorado * ama: 39-44 years old and/or * dor: amh \ 10 (age independent) exclusion criteria: * contraindication for pregnancy * have not fulfilled requirements for ivf cycle * single gene couple or chromosomal rearrangement * severe male factor or testicular surgical sperm removal (need sufficient sperm for icsi) * one ovary * uterine anomalies * stage iii or iv endometriosis * explained recurrent miscarriage * pco or pcos * using donor oocyte or gestational carrier
single injection infromedial peribulbar injection in lacrimal duct

Conditions: Pain Due to Certain Specified Procedures

Summary: infromedial injection of 3 ml local anesthetic drugs and assessing the pain during lacrimal duct intubation and probability of false tracking

after entering the or; the patient will be cannulated and fully monitored with basic monitors (pulse oximeter, nibp \& ecg), a nasal cannula is connected to the patient to deliver oxygen. we gave the patient 5 ml of propofol to decrease the discomfort felt by the patient during injection of local anesthesia. benox eye drops is applied to the operative eye in both groups. patients were allocated into 2 groups; each group is 25 patients group 1: we used a 25g/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 iu hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin. group 2: we used a 25g/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 iu hyaluronic acid classical medial canthal injection during surgery, we will assess the pain degree during probing using verbal rating scale (0 to 10 scale where 0 is no pain an 10 is unbearable pain), to assess the efficiency of this single low volume injection.

Eligibility criteria:
inclusion criteria: * adults undergoing lacrimal duct intubation surgery * patients' physical status by the american association of anesthesiology (asa): asa i, ii, iii. * age between 18-70, both sexes. * axial lengths ranging between 22-28mm. exclusion criteria: * asa iv. * patient age less than 18 or more than 70 years. * coagulation disorders (e.g. patients on warfarin (inr\<1.5) * communication difficulties preventing reliable assessment. * high myopia (axial length more than 28mm) and medial staphylomas.
impact of expired carbon monoxide measurement on smoking cessation of pregnant women

Conditions: Smoking Cessation

Summary: france is the country of europe where the prevalence of pregnant women smokers is the highest (35.9% before pregnancy and in the 3rd quarter 21.8% in 2008). in the investigator's country, among the smokers of early pregnancy with the usual care, only 30% manage to stop during pregnancy. maternal smoking during pregnancy is a clearly identified risk factor for the course of pregnancy and the unborn child. the measurement of carbon monoxide (co) expired in pregnancy monitoring consultation is part of the recommendations of the consensus conference "pregnancy and tobacco" (anaes, october 2004) and the parliamentary report on smoking by jl touraine and d. jacquat (feb 2012). however, this recommendation has not entered the current practice. the research aims to justify the clinical relevance of this recommendation by demonstrating the positive impact of expired co measurement on the rate of discontinuation during pregnancy.


Eligibility criteria:
inclusion criteria : group of smoking pregnant women (n = 600): * pregnant women declaring themselves smokers (at least one cigarette a day). * aged at least 18 years old. * consultant at limoges university hospital before the 24th week of amenorrhea. * desiring to be followed for their entire pregnancy at the children's. * desiring to give birth at the children's. * accepting to participate in the study group of strictly non-smoking pregnant women (n = 50): * pregnant women : * declaring not to be a smoker (to have been totally weaned for more than one year and to have smoked less than 100 cigarettes in her lifetime) before the beginning of the current pregnancy, and * whose partner and family do not smoke, and * not significantly exposed to tobacco (in their professional environment in particular), and * with a co measurement expired \<3 ppm. * aged at least 18 years old. * consultant at limoges university hospital before the 24th sa. * desiring to be followed for all their pregnancy and give birth at the children's hospital of limoges. * accepting to participate in the study. exclusion criteria : group of smoking pregnant women (n = 600) : * women with the following social and / or legal criteria: guardianship, curatorship, safeguard of justice. * women unable to understand the objectives of the study and the constraints of the protocol. group of strictly non-smoking pregnant women (n = 50) : * women with the following social and / or legal criteria: guardianship, curatorship, safeguard of justice. * women unable to understand the objectives of the study and the constraints of the protocol. * women with high blood pressure * diabetic woman * woman with hypothyroidism

Keywords: tobacco pregnancy addictive pregnant women stop smoking
a research study comparing wegovy to other weight management drugs in people living with obesity in america

Conditions: Obesity

Summary: the purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three us-based employers. these employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. the study will also look at how weight loss affects physical functioning, quality of life and ability to work. it will also gather information on how satisfied participants are with the medication they take. participants will either receive semaglutide or one of 4 approved anti-obesity medication (xenical/qsymia/contrave/saxenda).


Eligibility criteria:
inclusion criteria: * body mass index (bmi) greater than equal to 30.0 kilogram per meter square (kg/m\^2). * employed at randomisation by one of the selected employers and expecting to be so for the duration of the study. exclusion criteria: * known or suspected hypersensitivity or contraindications to wegovy or related products according to the label. * known or suspected hypersensitivity or contraindications to all of the other anti-obesity medications (aoms) for chronic weight management (xenical, qsymia, contrave, and saxenda) or related products according to the labels. * female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method. * history of type 1 or type 2 diabetes mellitus. * any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.